U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    PSMB9 proteasome 20S subunit beta 9 [ Homo sapiens (human) ]

    Gene ID: 5698, updated on 17-Jun-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses.

    Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses.
    Hu X, Hu Z, Zhang H, Zhang N, Feng H, Jia X, Zhang C, Cheng Q.

    01/10/2024
    Immunohistochemical Identification and Assessment of the Location of Immunoproteasome Subunits LMP2 and LMP7 in Acquired Cholesteatoma.

    Immunohistochemical Identification and Assessment of the Location of Immunoproteasome Subunits LMP2 and LMP7 in Acquired Cholesteatoma.
    Rutkowska J, Kasacka I, Rogowski M, Olszewska E., Free PMC Article

    09/30/2023
    Immunoproteasome-specific subunit PSMB9 induction is required to regulate cellular proteostasis upon mitochondrial dysfunction.

    Immunoproteasome-specific subunit PSMB9 induction is required to regulate cellular proteostasis upon mitochondrial dysfunction.
    Kim M, Serwa RA, Samluk L, Suppanz I, Kodroń A, Stępkowski TM, Elancheliyan P, Tsegaye B, Oeljeklaus S, Wasilewski M, Warscheid B, Chacinska A., Free PMC Article

    07/13/2023
    Variants in PSMB9 and FGR differentially affect Parkinson's disease risk in GBA and LRRK2 mutation carriers.

    Variants in PSMB9 and FGR differentially affect Parkinson's disease risk in GBA and LRRK2 mutation carriers.
    Shani S, Goldstein O, Gana-Weisz M, Bar-Shira A, Thaler A, Gurevich T, Mirelman A, Giladi N, Alcalay RN, Orr-Urtreger A.

    06/15/2023
    Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers.

    Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers.
    Geoffroy K, Araripe Saraiva B, Viens M, Béland D, Bourgeois-Daigneault MC., Free PMC Article

    03/1/2023
    Identification of PSMB9 and CXCL13 as Immune-related Diagnostic Markers for Rheumatoid Arthritis by Machine Learning.

    Identification of PSMB9 and CXCL13 as Immune-related Diagnostic Markers for Rheumatoid Arthritis by Machine Learning.
    Li Z, Chen Y, Zulipikaer M, Xu C, Fu J, Deng T, Hao LB, Chen JY.

    11/12/2022
    Transcriptome-wide association study identifies PSMB9 as a susceptibility gene for coal workers' pneumoconiosis.

    Transcriptome-wide association study identifies PSMB9 as a susceptibility gene for coal workers' pneumoconiosis.
    Yuan J, Wang T, Wang L, Li P, Shen H, Mo Y, Zhang Q, Ni C.

    07/16/2022
    Heterozygous missense variant of the proteasome subunit beta-type 9 causes neonatal-onset autoinflammation and immunodeficiency.

    Heterozygous missense variant of the proteasome subunit β-type 9 causes neonatal-onset autoinflammation and immunodeficiency.
    Kanazawa N, Hemmi H, Kinjo N, Ohnishi H, Hamazaki J, Mishima H, Kinoshita A, Mizushima T, Hamada S, Hamada K, Kawamoto N, Kadowaki S, Honda Y, Izawa K, Nishikomori R, Tsumura M, Yamashita Y, Tamura S, Orimo T, Ozasa T, Kato T, Sasaki I, Fukuda-Ohta Y, Wakaki-Nishiyama N, Inaba Y, Kunimoto K, Okada S, Taketani T, Nakanishi K, Murata S, Yoshiura KI, Kaisho T., Free PMC Article

    12/25/2021
    Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor.

    Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor.
    Kataoka S, Kawashima N, Okuno Y, Muramatsu H, Miwata S, Narita K, Hamada M, Murakami N, Taniguchi R, Ichikawa D, Kitazawa H, Suzuki K, Nishikawa E, Narita A, Nishio N, Yamamoto H, Fukasawa Y, Kato T, Yamamoto H, Natsume J, Kojima S, Nishino I, Taketani T, Ohnishi H, Takahashi Y.

    10/23/2021
    The dominant model of LMP2 CfoI might be a risk factor for IDDM in Asian population. Whereas, the allelic and dominant models of LMP7 G37360T might be protective factors for IDDM in Caucasian population

    The genetic association between LMP2 and LMP7 polymorphisms and susceptibility of insulin dependent diabetes mellitus: A meta-analysis.
    Xu Y, Liu G, Zhou Y, Lu Z, Shi Z, Wang J., Free PMC Article

    04/18/2020
    the allelic model of LMP2 CfoI might be a protective factor for ankylosing spondylitis in the Caucasian population (Meta-Analysis)

    The LMP2 CfoI polymorphism is associated with ankylosing spondylitis (AS) risk but not with acute anterior uveitis (AAU): A meta-analysis.
    Qian Y, Chen B, Sheng X, Peng Y., Free PMC Article

    01/18/2020
    co-inhibition of LMP2 and LMP7 appears to be synergistic and advantageous for the treatment of autoimmune diseases.

    Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.
    Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, Maurits E, Tsu C, Overkleeft HS, Kirk CJ, Langrish CL, Groettrup M., Free PMC Article

    07/20/2019
    Defective PSMB9/beta1i expression is likely to be one of the risk factors for the development of human uterine neoplasm.

    A novel diagnostic biomarker for human uterine leiomyosarcoma: PSMB9/β1i.
    Hayashi T, Kawano M, Sano K, Ichimura T, Gur G, Yaish P, Zharhary D, Kanai Y, Tonegawa S, Shiozawa T, Yaegashi N, Konishi I.

    08/25/2018
    single nucleotide polymorphism in PSMB9 are associated with hand dermatitis

    Association of MHC region SNPs with irritant susceptibility in healthcare workers.
    Yucesoy B, Talzhanov Y, Michael Barmada M, Johnson VJ, Kashon ML, Baron E, Wilson NW, Frye B, Wang W, Fluharty K, Gharib R, Meade J, Germolec D, Luster MI, Nedorost S., Free PMC Article

    09/30/2017
    Data show that tight junction protein 1 (TJP1) suppressed expression of the catalytically proteasome subunits LMP7 and LMP2, decreased proteasome activity, and enhanced proteasome inhibitor sensitivity in vitro and in vivo through suppression of EGFR/JAK1/STAT3 signaling.

    Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
    Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ., Free PMC Article

    04/1/2017
    Chinese females carrying the rs17587-G/G genotype in PSMB9 may increase a higher risk for Parkinson's disease.

    Association Analysis of Proteasome Subunits and Transporter Associated with Antigen Processing on Chinese Patients with Parkinson's Disease.
    Mo MS, Huang W, Sun CC, Zhang LM, Cen L, Xiao YS, Li GF, Yang XL, Qu SG, Xu PY., Free PMC Article

    03/11/2017
    designed siRNAs that efficiently silence LMP2, LMP7 and MECL-1 gene expression.

    Modified siRNA effectively silence inducible immunoproteasome subunits in NSO cells.
    Gvozdeva OV, Belogurov AA Jr, Kuzina ES, Gabibov AG, Meschaninova MI, Ven'yaminova AG, Zenkova MA, Vlassov VV, Chernolovskaya EL.

    01/14/2017
    The TAP1-rs1135216 and PSMB9-rs17587 variants are significantly associated with vitiligo, and even one copy of these mutant alleles can influence the risk among Saudis.

    Transporter TAP1-637G and immunoproteasome PSMB9-60H variants influence the risk of developing vitiligo in the Saudi population.
    Elhawary NA, Bogari N, Jiffri EH, Rashad M, Fatani A, Tayeb M., Free PMC Article

    08/1/2015
    Comparison with reference profiles of sorted immune cells and healthy muscle confirmed upregulation of PSMB8 and -9 in myositis biopsies beyond infiltration related changes.

    Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFNΓ.
    Ghannam K, Martinez-Gamboa L, Spengler L, Krause S, Smiljanovic B, Bonin M, Bhattarai S, Grützkau A, Burmester GR, Häupl T, Feist E., Free PMC Article

    04/18/2015
    study found prevalence of LMP2-AA genotype was higher in acute myeolid leukemia (AML) patients while it was significantly lower in multiple myeloma (MM) cases than in the control subjects; results suggestLMP2 polymorphisms could play a role in the development of AML and MM

    Association of an LMP2 polymorphism with acute myeloid leukemia and multiple myeloma.
    Ozbas-Gerceker F, Bozman N, Kok S, Pehlivan M, Yilmaz M, Pehlivan S, Oguzkan-Balci S.

    02/28/2015
    Data indicate that the codon 60 Arg/His polymorphism does not significantly alter the expression and activity of beta1i among the cell lines tested and clinical samples from colon and pancreatic cancer.

    PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit B1i expressed in multiple types of solid cancer.
    Park JE, Ao L, Miller Z, Kim K, Wu Y, Jang ER, Lee EY, Kim KB, Lee W., Free PMC Article

    07/5/2014
    The data show that LMP2 and PSMA6 gene polymorphism is not a risk factor of ischemic stroke in Ukrainian population.

    [Frequency of allele polymorphism of immune proteasome catalytic subunits in patients with ischemic stroke].
    Savchuk OI, Mel'nyk VS, Goncharov SV, Shandiuk VIu, Stroĭ DO, Dosenko VIe, Sokolova LI, Skybo HH.

    06/7/2014
    functional variants in PSMB9 may contribute to melanoma susceptibility.

    Association between putative functional variants in the PSMB9 gene and risk of melanoma--re-analysis of published melanoma genome-wide association studies.
    Qian J, Liu H, Wei S, Liu Z, Li Y, Wang LE, Chen WV, Amos CI, Lee JE, GenoMEL investigators, Iles MM, Law MH, Q-MEGA AMFS investigators, Cust AE, Barrett JH, Montgomery GW, Taylor J, Bishop JA, Macgregor S, Bishop DT, Mann GJ, Hayward NK, Wei Q., Free PMC Article

    11/23/2013
    LMP2 has a role as a tumor-suppressor and may have a role in uterine leiomyosarcoma therapy

    Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy.
    Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kasai M, Ichimura T, Sudo T, Tagawa Y, Nishimura R, Ishiko O, Kanai Y, Yaegashi N, Aburatani H, Shiozawa T, Konishi I., Free PMC Article

    09/14/2013
    Genetic polymorphisms of rs17587 of PSMB9 appeared to be associated with rheumatoid arthritis in ethnic Han Chinese from Yunnan.

    [Association between polymorphisms of PSMB8, PSMB9 and TAP2 genes with rheumatoid arthritis in ethnic Han Chinese from Yunnan].
    Yu L, Li Q, Lin J, Yu J, Li Q, Yi W, Sun H, Chu JY, Yang ZQ.

    07/27/2013
    firstprevious page of 3 nextlast